Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward
Deal Struck With UK On Coronavirus Vaccine
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
You may also be interested in...
While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.